auto-fix: strip 8 broken wiki links

Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.

domains/health/four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable.md

@@ -1,12 +1,12 @@
 ---
+description: Four models compete for VBC dominance -- the integrated behemoth (Optum) the aligned partner (Devoted) the risk clearinghouse and the consumer health partner (Kaiser) -- with vertical integration winning on market share but facing antitrust headwinds that may favor partnership approaches
 type: claim
 domain: health
-description: Four models compete for VBC dominance -- the integrated behemoth (Optum) the aligned partner (Devoted) the risk clearinghouse and the consumer health partner (Kaiser) -- with vertical integration winning on market share but facing antitrust headwinds that may favor partnership approaches
-confidence: likely
-source: SDOH/VBC research synthesis February 2026; Healthcare Dive Optum pricing study; DOJ antitrust investigations 2025; Devoted Health star ratings 2026
 created: 2026-02-17
-sourced_from: ["inbox/archive/health/2026-03-22-openevidence-sutter-health-epic-integration.md"]
-related: ["four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable", "Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening"]
+source: "SDOH/VBC research synthesis February 2026; Healthcare Dive Optum pricing study; DOJ antitrust investigations 2025; Devoted Health star ratings 2026"
+confidence: likely
+sourced_from:
+- inbox/archive/health/2026-03-22-openevidence-sutter-health-epic-integration.md
 ---
 
 # four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable
@@ -37,10 +37,3 @@ Relevant Notes:
 
 Topics:
 - health and wellness
-
-
-## Supporting Evidence
-
-**Source:** HCPLAN 2024 survey, CMS mandatory ASM and REACH models
-
-88.5 million lives now in Categories 3+4 accountable care arrangements (downside risk). CMS policy acceleration through mandatory models (Ambulatory Specialty Model for heart failure/low back pain) and REACH Model full-risk option (100% savings/losses) demonstrates federal commitment to forcing structural transition regardless of voluntary adoption pace.

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -81,10 +81,3 @@ ICER report documents the access inversion at policy level: California Medi-Cal
 **Source:** on/healthcare.tech coverage expansion analysis
 
 Coverage expansion data shows 43% of 5,000+ employee firms now cover GLP-1s for weight loss (up from 28% in 2024), while state mandates are emerging (North Dakota January 2025, California/Connecticut/West Virginia introducing legislation). However, Medicare Part D coverage doesn't begin until January 2027, and Medicaid coverage is reversing through state budget pressure. This confirms the access inversion where higher-income commercially insured populations gain access while lower-income populations face coverage contraction.
-
-
-## Extending Evidence
-
-**Source:** DistilINFO April 2026
-
-Coverage withdrawal is concentrated among regional health systems (Allina, RWJBarnabas, Ascension, Hennepin) and state employee plans (Ohio, Idaho, Louisiana, Massachusetts), while large sophisticated employers maintain coverage with behavioral mandates. This creates a new layer of access inversion where mid-market and public sector populations lose coverage entirely.

domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md

@@ -13,7 +13,7 @@ related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category
 supports: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients"]
 reweave_edges: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|supports|2026-04-14", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14"]
 sourced_from: ["inbox/archive/health/2026-04-13-kff-glp1-access-inversion-by-state-income.md"]
-related: ["glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access"]
+related: ["glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence"]
 ---
 
 # GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
@@ -39,10 +39,3 @@ The Medicare GLP-1 Bridge program demonstrates that access inversion operates at
 **Source:** KFF 2025 poll condition-specific usage
 
 Among patients with diagnosed conditions showing clear clinical benefit, uptake remains limited: 45% of diabetes patients and 29% of heart disease patients currently using GLP-1s. Even in populations with established medical indication and likely insurance coverage, majority non-uptake persists. The 56% affordability difficulty rate among current users demonstrates cost barriers operate even after initial access is achieved.
-
-
-## Extending Evidence
-
-**Source:** HR Brew December 2025, 9amHealth partnership announcements
-
-The utilization vs. coverage divergence is now quantified: GLP-1 usage among surveyed populations (likely employer benefits) has 'more than doubled since 2023, reaching 49%' while total covered lives declined 22% (3.6M → 2.8M). This creates a dual-track access system where those who maintain coverage show dramatically higher utilization, while total population-level access worsens. The 9amHealth No-Barriers Bundle integrates medications from both Eli Lilly and Novo Nordisk at fixed monthly costs, but is only in discussions with employer groups as of early 2026 with no disclosed enrollment.

domains/health/glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift.md

@@ -11,16 +11,9 @@ sourced_from: health/2026-04-28-phti-employer-glp1-coverage-behavioral-mandate-2
 scope: structural
 sourcer: Peterson Health Technology Institute
 supports: ["glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024"]
-related: ["glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary"]
+related: ["glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support"]
 ---
 
 # GLP-1 behavioral support mandates tripled in one year (10% to 34%) signaling structural shift from drug-only formulary to managed-access operating systems
 
 PHTI's December 2025 employer survey found that 34% of firms covering GLP-1s now require dietitian, case management, therapy, or lifestyle participation as a coverage condition, up from 10% the prior year—a 3.4x increase in 12 months. This is not incremental adoption but structural acceleration. Three major payers have operationalized this shift: Evernorth EncircleRx (9M lives, $200M saved since 2024), Optum Rx Weight Engage (coaching + specialist navigation), and UHC Total Weight Support (mandates Real Appeal Rx or WeightWatchers as coverage prerequisite). The mandate rate acceleration coincides with 77% of large employers rating GLP-1 cost management as 'extremely or very important' for 2026, and 59% reporting utilization exceeding expectations. The shift is driven by economic necessity: 36.2M eligible commercially insured adults × $1,000-1,200/month creates fiscal unsustainability under traditional yes/no formulary logic. Payers are building what PHTI calls 'managed-access operating systems' covering population qualification, channel routing, behavioral gates, subsidy levels, and discontinuation rules. This is infrastructure, not incremental policy adjustment.
-
-
-## Extending Evidence
-
-**Source:** DistilINFO April 2026 citing Leverage|Axiaci December 2025
-
-The behavioral mandate acceleration (34% of employers requiring support, up from 10%) is occurring simultaneously with a 22% decline in total covered lives (3.6M to 2.8M), suggesting market bifurcation: large sophisticated employers add managed-access infrastructure while regional payers and mid-market employers drop coverage entirely. The two trends are compatible but create divergent access pathways.

domains/health/glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-28-glp1-market-stratification-access-first-vs-clini
 scope: structural
 sourcer: Vida synthesis
 supports: ["healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create", "the-healthcare-attractor-state-is-a-prevention-first-system-where-aligned-payment-continuous-monitoring-and-ai-augmented-care-delivery-create-a-flywheel-that-profits-from-health-rather-than-sickness"]
-related: ["glp1-long-term-persistence-ceiling-14-percent-year-two", "healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create", "the-healthcare-attractor-state-is-a-prevention-first-system-where-aligned-payment-continuous-monitoring-and-ai-augmented-care-delivery-create-a-flywheel-that-profits-from-health-rather-than-sickness", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt", "cgm-integrated-glp1-behavioral-support-achieves-superior-unit-economics-versus-coaching-only-models", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift"]
+related: ["glp1-long-term-persistence-ceiling-14-percent-year-two", "healthcares-defensible-layer-is-where-atoms-become-bits-because-physical-to-digital-conversion-generates-the-data-that-powers-ai-care-while-building-patient-trust-that-software-alone-cannot-create", "the-healthcare-attractor-state-is-a-prevention-first-system-where-aligned-payment-continuous-monitoring-and-ai-augmented-care-delivery-create-a-flywheel-that-profits-from-health-rather-than-sickness", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "glp1-behavioral-support-market-stratifies-by-physical-integration-with-atoms-to-bits-companies-profitable-and-behavioral-only-companies-bankrupt"]
 ---
 
 # GLP-1 behavioral support market stratifies by physical integration level with atoms-to-bits companies achieving profitability while behavioral-only companies fail
@@ -31,10 +31,3 @@ LLM coaching research shows that message-level behavioral support can be replica
 **Source:** WeightWatchers bankruptcy filing May 2025, Axios, NPR
 
 WeightWatchers' bankruptcy validates the stratification thesis with extreme clarity. WW had $700M revenue but required $1.15B debt elimination to survive (70% debt reduction). The $106M Sequence acquisition in 2023 added telehealth prescribing but came 'too late and lacked scale' — competitors Ro, Found, Calibrate, and Hims had already established the telehealth-GLP-1 market. Post-bankruptcy transformation to 'clinical-behavioral hybrid' still shows no CGM or physical monitoring integration. Unit economics comparison: WW at $700M = leveraged and breaking; Omada at $260M with CGM = profitable and growing 55% YoY.
-
-
-## Challenging Evidence
-
-**Source:** PredictStreet analysis, January 2026
-
-WeightWatchers post-bankruptcy strategy (July 2025) explicitly avoids CGM integration despite the natural experiment showing Omada (CGM + behavioral) achieved profitable IPO while WW (behavioral-only) went bankrupt. WW's rebirth focuses on AI Body Scanner (smartphone-based) and consumer wearable data aggregation rather than clinical-grade physical monitoring. CEO Tara Comonte positions WW Clinic as 'clinical space' player through GLP-1 prescribing + behavioral support, but without the atoms-to-bits layer that Session 30 identified as the winning model. This creates a live test case: if WW Clinic achieves clinical outcomes without physical monitoring, it challenges the scope of the atoms-to-bits defensibility thesis.

domains/health/glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap.md

@@ -1,20 +0,0 @@
----
-type: claim
-domain: health
-description: "Enrolled lives in employer-sponsored GLP-1 weight-loss coverage dropped 22% from 3.6M (2024) to 2.8M (2026) as major health systems and insurers withdraw coverage"
-confidence: likely
-source: "DistilINFO citing Leverage|Axiaci December 2025 analysis"
-created: 2026-04-29
-title: GLP-1 weight-loss coverage is declining at the employer and health system level despite rising utilization creating a widening access gap driven by cost pressures that exceed VBC cost management capacity
-agent: vida
-sourced_from: health/2026-04-29-employer-glp1-coverage-crisis-enrollment-declining-2026.md
-scope: structural
-sourcer: DistilINFO Publications
-supports: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk"]
-challenges: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
-related: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary"]
----
-
-# GLP-1 weight-loss coverage is declining at the employer and health system level despite rising utilization creating a widening access gap driven by cost pressures that exceed VBC cost management capacity
-
-Covered individuals enrolled in employer-sponsored GLP-1 weight-loss coverage declined from 3.6 million in 2024 to 2.8 million in 2026, a 22% decrease, even as overall GLP-1 utilization continues rising. Major health systems have discontinued coverage entirely: Allina Health, RWJBarnabas Health, Ascension, and Hennepin Healthcare all withdrew coverage. Fairview Health Services targeted $10M+ in savings through restrictions. Kaiser Permanente cut California commercial and ACA member coverage in early 2025. Mass General Brigham Health Plan ended coverage for small employers and individual members. State employee plans in Ohio, Idaho, Louisiana, and Massachusetts don't cover weight-loss GLP-1s. The cost crisis is documented: Blue Cross Blue Shield Michigan reported a $350M increase in GLP-1 drug costs in 2023 alone. Blue Cross Blue Shield Massachusetts reported a $400M operating loss in 2024 driven largely by GLP-1 spending. This represents a structural retreat from coverage, not just cost pressure. The coverage withdrawal is occurring simultaneously with the behavioral mandate acceleration documented in Session 30 (34% of employers now require behavioral support, up from 10%), suggesting market bifurcation: sophisticated large employers add managed-access infrastructure while regional payers and mid-market employers drop coverage entirely. The net effect is declining access despite rising clinical need.

domains/health/glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-23-icer-glp1-affordable-access-2025.md
 scope: structural
 sourcer: ICER
 supports: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medicaid-glp1-coverage-reversing-through-state-budget-pressure"]
-related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift"]
+related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024"]
 ---
 
 # GLP-1 obesity coverage creates acute payer fiscal crisis with employer plans experiencing >10x PMPM cost increases in 2023-2024 and major insurers reporting operating losses driven primarily by GLP-1 expenditures
@@ -31,10 +31,3 @@ Employer response to GLP-1 cost pressure includes cost management strategies: st
 **Source:** on/healthcare.tech, Evernorth EncircleRx operational data
 
 Evernorth EncircleRx reports ~$200 million saved since 2024 across 9 million enrolled lives through 15% cost cap or 3:1 savings guarantee structure. This represents early evidence that managed-access infrastructure can contain costs, though the $200M savings across 9M lives (~$22/member) is modest relative to the 10x PMPM increase that created the fiscal pressure.
-
-
-## Supporting Evidence
-
-**Source:** DistilINFO April 2026
-
-Blue Cross Blue Shield Michigan reported $350M increase in GLP-1 drug costs in 2023 alone. Blue Cross Blue Shield Massachusetts reported $400M operating loss in 2024 driven largely by GLP-1 spending. These are major regional Blues plans with broad population coverage, confirming the fiscal unsustainability is affecting diverse payer types, not just large employers.

domains/health/hospital-price-transparency-produces-cost-reductions-only-for-self-pay-elective-procedures-not-insured-patients.md

@@ -1,19 +0,0 @@
----
-type: claim
-domain: health
-description: Market competition via price transparency is structurally limited to a minority of healthcare spending, leaving FFS payment incentives unchanged
-confidence: likely
-source: "Pan & Yaraghi SAGE 2025, Mathematica, Brookings"
-created: 2026-04-29
-title: Hospital price transparency rules produce measurable cost reductions only for self-pay patients seeking elective procedures while insured patients show no behavioral change because insurance insulates them from marginal cost
-agent: vida
-sourced_from: health/2026-04-29-price-transparency-limited-insured-market-impact-2025.md
-scope: structural
-sourcer: "Multiple sources: Mathematica, SAGE Journals, Brookings, CMS"
-supports: ["proxy-inertia-is-the-most-reliable-predictor-of-incumbent-failure-because-current-profitability-rationally-discourages-pursuit-of-viable-futures"]
-related: ["value-based-care-transitions-stall-at-the-payment-boundary-because-60-percent-of-payments-touch-value-metrics-but-only-14-percent-bear-full-risk", "proxy-inertia-is-the-most-reliable-predictor-of-incumbent-failure-because-current-profitability-rationally-discourages-pursuit-of-viable-futures"]
----
-
-# Hospital price transparency rules produce measurable cost reductions only for self-pay patients seeking elective procedures while insured patients show no behavioral change because insurance insulates them from marginal cost
-
-Multiple 2025 studies show hospital price transparency compliance remains poor (55% of hospitals had not posted readable price files 6 months after rule took effect) and market impact is highly selective. Pan & Yaraghi's SAGE 2025 analysis found that transparency 'does NOT broadly reduce hospital charges' but 'DOES lead to lower charges for self-pay patients opting for elective procedures who are sensitive to price and can shop.' Critically, 'behavioral changes were NOT observed for insured patients.' The mechanism is structural: insured patients typically owe copay/deductible amounts, not full prices, so price transparency doesn't change their marginal cost. Provider networks (HMO, narrow network plans) further limit patient choice regardless of price knowledge. Emergency care, specialist referrals, and surgery remain non-shoppable. Brookings estimated potential savings of $80.1 billion using a 40% reduction in shoppable service expenditures, but this assumes behavioral change that hasn't materialized for the insured majority. The evidence shows market competition works only at the margins (self-pay elective procedures) while the bulk of healthcare spending remains structurally insulated from consumer price pressure. FFS payment incentives operate at the payer-provider level, not the consumer level, and price transparency doesn't touch this layer.

domains/health/manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-28-glp1-managed-access-operating-systems-payer-infr
 scope: structural
 sourcer: on/healthcare.tech
 challenges: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
-related: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression"]
+related: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
 ---
 
 # Manufacturer direct-to-employer GLP-1 channels launched 2026 represent structural challenge to PBM intermediation by offering 55-60 percent price compression while bypassing traditional pharmacy benefit architecture
@@ -39,17 +39,3 @@ But the structural challenge is real: if manufacturers can profitably deliver GL
 **Source:** PHTI December 2025 employer report
 
 Eli Lilly Employer Connect launched March 5, 2026 at $449/dose with partnerships across 15+ program administrators (GoodRx, Teladoc, Calibrate, Form Health, Waltz). Novo Nordisk launched parallel DTE with Waltz Health and 9amHealth on January 1, 2026. Both manufacturers are bundling behavioral support infrastructure into the DTE channel, not just offering price compression.
-
-
-## Supporting Evidence
-
-**Source:** HR Brew/PR Newswire Q4 2025-Q1 2026 DTE announcements
-
-Both major GLP-1 manufacturers (Eli Lilly via Employer Connect, Novo Nordisk via 9amHealth/Waltz Health partnerships) now operate DTE channels as of Q1 2026. Novo's Waltz Health DTE program launched January 1, 2026 for FDA-approved obesity medications. 9amHealth's No-Barriers Bundle integrates access to medications from both manufacturers at fixed monthly costs. However, neither manufacturer has disclosed enrollment data or market penetration, and expert consensus characterizes DTE as 'manufacturers positioning themselves as more active participants in employer access strategy' rather than structural displacement of PBM intermediation.
-
-
-## Challenging Evidence
-
-**Source:** MedCity News / National Alliance expert assessment, March 2026
-
-Lilly Employer Connect's $449/month net price for Zepbound 'doesn't appear to be substantially lower than the price employers were already getting' through existing PBM channels according to National Alliance of Healthcare Purchaser Coalitions expert. Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) still control approximately 80% of US prescription claims. The DTE channel represents a 'governance shift rather than structural disruption' per Sequoia analysis - manufacturers becoming direct participants in employer benefit design rather than achieving price disruption.

domains/health/medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-transformation-from-supplement-to-dominant-program.md

@@ -1,14 +1,17 @@
 ---
+
 type: claim
 domain: health
 description: "MA enrollment reached 51% in 2023 and 54% by 2025, with CBO projecting 64% by 2034, making traditional Medicare the minority program"
 confidence: proven
 source: "Kaiser Family Foundation, Medicare Advantage in 2025: Enrollment Update and Key Trends (2025)"
 created: 2025-07-24
-supports: ["chronic-condition-special-needs-plans-grew-71-percent-in-one-year-indicating-explosive-demand-for-disease-management-infrastructure"]
-reweave_edges: ["chronic-condition-special-needs-plans-grew-71-percent-in-one-year-indicating-explosive-demand-for-disease-management-infrastructure|supports|2026-03-28"]
-sourced_from: ["inbox/archive/health/2025-07-24-kff-medicare-advantage-2025-enrollment-update.md"]
-related: ["medicare-advantage-crossed-majority-enrollment-in-2023-marking-structural-transformation-from-supplement-to-dominant-program"]
+supports:
+- chronic-condition-special-needs-plans-grew-71-percent-in-one-year-indicating-explosive-demand-for-disease-management-infrastructure
+reweave_edges:
+- chronic-condition-special-needs-plans-grew-71-percent-in-one-year-indicating-explosive-demand-for-disease-management-infrastructure|supports|2026-03-28
+sourced_from:
+- inbox/archive/health/2025-07-24-kff-medicare-advantage-2025-enrollment-update.md
 ---
 
 # Medicare Advantage crossed majority enrollment in 2023 marking structural transformation from supplement to dominant program
@@ -48,10 +51,3 @@ Relevant Notes:
 
 Topics:
 - domains/health/_map
-
-
-## Extending Evidence
-
-**Source:** HCPLAN 2024 survey covering 282.9M lives across all payer types
-
-MA market disruptions (UHG losses, Humana market exits) have NOT slowed broader VBC adoption trend. HCPLAN data covers all insurance types (not just MA), showing 28.5% downside risk penetration across commercial, Medicaid, and Medicare FFS. The structural transition has momentum independent of MA-specific turbulence.

domains/health/mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates.md

@@ -1,18 +0,0 @@
----
-type: claim
-domain: health
-description: Payers actively raise reimbursement to attract medical providers when network gaps exist but do not apply the same methodology to mental health provider networks, creating a structural mechanism that perpetuates access barriers independent of coverage mandates
-confidence: experimental
-source: DOL EBSA, 2025 MHPAEA Report to Congress
-created: 2026-04-29
-title: MHPAEA enforcement closes coverage gaps but not access gaps because payers differentially treat mental health versus medical reimbursement rates
-agent: vida
-sourced_from: health/2026-04-29-mhpaea-fourth-report-2025-enforcement-structural-limits.md
-scope: structural
-sourcer: DOL EBSA
-related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access"]
----
-
-# MHPAEA enforcement closes coverage gaps but not access gaps because payers differentially treat mental health versus medical reimbursement rates
-
-The 2025 MHPAEA Report to Congress documents a specific structural mechanism explaining why mental health parity enforcement improves coverage mandates without closing access gaps. EBSA found multiple instances where plan sponsors and issuers 'actively increased reimbursement rates for certain M/S [medical/surgical] providers as a strategy to attract and retain service providers where they found insufficiency in the network' but 'the same methodologies were NOT utilized to attract and retain MH/SUD providers, even where gaps were identified in MH/SUD provider networks.' This is not passive neglect or ignorance—it is documented differential treatment at the operational level. Payers demonstrate they know how to fix network adequacy problems (raise reimbursement rates) and actively deploy this strategy for medical networks, but deliberately choose not to apply it to mental health networks. This creates a structural barrier that persists independently of coverage mandates: even when plans are required to cover mental health services at parity, the supply-side incentive structure remains broken because payers won't pay enough to attract providers. The enforcement actions documented in the report (dozens of actions, $100K-$2M+ penalties) target coverage compliance and NQTL documentation, but cannot compel payers to raise reimbursement rates. The report's focus on enforcement actions without corresponding access outcome metrics (reduced wait times, more in-network providers) suggests that compliance improvements are not translating to access improvements. This mechanism explains why strong enforcement (2024 rule with new NQTL comparative analysis requirements, network adequacy standards, ABA/MAT exclusion coverage mandates) coexists with persistent access barriers.

domains/health/mssp-acos-generate-record-savings-while-improving-quality-proving-cost-quality-cooptimization.md

@@ -1,26 +0,0 @@
----
-type: claim
-domain: health
-description: "CMS MSSP 2024 results show ACOs outperformed non-ACO groups on depression screening (53.53% vs 44.42%), blood pressure control (71.21% vs 67.82%), and cancer screening while generating $2.48B net savings, defeating the under-treatment critique of value-based care"
-confidence: proven
-source: CMS Medicare Shared Savings Program 2024 Performance Year Results, September 2025
-created: 2026-04-29
-title: MSSP ACOs generated record $2.48B in net Medicare savings in 2024 for the eighth consecutive year while maintaining superior quality performance compared to non-ACO peers proving that cost and quality improvement are achievable simultaneously under value-based payment
-agent: vida
-sourced_from: health/2026-04-29-cms-mssp-py2024-2-4b-savings-vbc-structural-proof.md
-scope: structural
-sourcer: "Centers for Medicare & Medicaid Services"
-supports: ["the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness"]
-related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness"]
----
-
-# MSSP ACOs generated record $2.48B in net Medicare savings in 2024 for the eighth consecutive year while maintaining superior quality performance compared to non-ACO peers proving that cost and quality improvement are achievable simultaneously under value-based payment
-
-The 2024 MSSP results provide the strongest empirical evidence that value-based care's structural fix thesis works at scale. ACOs generated $2.48B in net Medicare savings (after shared savings payments) for the eighth consecutive year, with per capita net savings increasing from $207 in 2023 to $241 in 2024. Critically, this cost reduction occurred alongside quality improvements across multiple clinical domains. ACOs outperformed non-ACO physician groups on Screening for Depression and Follow-up Plan (53.53% vs 44.42%), Controlling High Blood Pressure (71.21% vs 67.82%), and showed improved performance on A1c control and cancer screening. This simultaneous cost-quality improvement directly refutes the central critique of value-based care: that cost reduction incentives will lead to under-treatment. The data shows the opposite pattern—ACOs are both more cost-effective AND deliver higher quality care. The acceleration is also notable: per capita gross savings increased $128 year-over-year (from $515 to $643), the largest single-year jump in the program's history. Two-thirds of ACOs now participate in downside risk tracks (Level E or Enhanced), generating $5.4B of the $6.6B in gross savings, demonstrating that the transition to full risk-bearing is advancing despite aggregate payment statistics showing only 14% of total healthcare payments bearing full risk.
-
-
-## Extending Evidence
-
-**Source:** Health Affairs 2024 MSSP analysis
-
-MSSP 2024 performance shows acceleration in per capita savings: $641 gross per capita (up $128 from 2023) and $241 net per capita (up $34 from 2023). This year-over-year increase in per capita savings suggests ACOs are exhibiting learning curve effects - getting better at value-based care over time rather than just selecting healthier populations. The quality improvements are specific and measurable: depression screening 53.5% vs 44.4% for non-ACO peers, blood pressure control 71.2% vs 67.8%, with cancer screening and A1c control also improving. This provides the strongest counter-evidence to the 'VBC under-treats to cut costs' concern - quality is improving alongside cost reduction, not trading off.

domains/health/mssp-downside-risk-adoption-accelerating-two-thirds-in-risk-tracks.md

@@ -1,25 +0,0 @@
----
-type: claim
-domain: health
-description: "MSSP 2024 data shows 67% of ACOs in Level E or Enhanced tracks generating $5.4B of $6.6B gross savings, with CMS 2026 rules making two-sided risk the default, indicating structural acceleration of value-based care adoption"
-confidence: proven
-source: CMS Medicare Shared Savings Program 2024 Performance Year Results, September 2025
-created: 2026-04-29
-title: Two-thirds of MSSP ACOs now participate in downside risk tracks generating more than two-thirds of all savings demonstrating that the transition to full risk-bearing is accelerating despite slow aggregate payment statistics
-agent: vida
-sourced_from: health/2026-04-29-cms-mssp-py2024-2-4b-savings-vbc-structural-proof.md
-scope: structural
-sourcer: "Centers for Medicare & Medicaid Services"
-related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk"]
----
-
-# Two-thirds of MSSP ACOs now participate in downside risk tracks generating more than two-thirds of all savings demonstrating that the transition to full risk-bearing is accelerating despite slow aggregate payment statistics
-
-The MSSP 2024 results reveal a critical structural shift in value-based care adoption that contradicts the narrative of stalled transition. Two-thirds of participating ACOs are now in Level E or Enhanced tracks—both of which include downside risk—and these risk-bearing ACOs generated $5.4B of the $6.6B in total gross savings (82% of all savings). This concentration of savings in risk-bearing arrangements demonstrates that full accountability drives superior performance. The transition is also accelerating institutionally: CMS 2026 rules make two-sided risk the default for new MSSP entrants and restrict one-sided participation, while simultaneously launching the Ambulatory Specialty Model (ASM) for heart failure and low back pain with mandatory risk-bearing. This policy direction directly contradicts the claim that value-based care adoption has stalled. The aggregate statistic showing only 14% of total healthcare payments bearing full risk reflects the SLOW PACE of transition across the entire healthcare system, not a failure of the model itself. Within MSSP—the largest federal value-based care program—the transition to risk-bearing is advancing rapidly, with two-thirds already participating and policy changes forcing the remainder to follow. The gap between MSSP's 67% risk-bearing rate and the healthcare system's 14% rate reveals that the bottleneck is adoption speed and policy will, not model viability.
-
-
-## Extending Evidence
-
-**Source:** Health Affairs 2024 MSSP analysis, CMS 2026 rules
-
-The two-thirds of ACOs now in Level E or Enhanced (downside risk) tracks generated $5.4B of the $6.6B total gross savings (82%), while representing two-thirds of participants. This creates a precise empirical claim: risk-bearing ACOs generate disproportionate savings relative to their share of participation. The 82% savings from 67% of ACOs demonstrates that downside risk adoption is not just growing in volume but is the high-performance tier of the MSSP program. CMS 2026 rules restricting one-sided participation (reducing cap from 7 to 5 years starting 2027) will accelerate this shift further.

domains/health/the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness.md

@@ -363,10 +363,3 @@ Topics:
 **Source:** Papanicolas et al., JAMA Internal Medicine 2025, OECD Health at a Glance 2025
 
 Current US system shows treatable mortality gap of 95 vs OECD average 77 per 100,000 (confirming clinical system underperformance) and preventable mortality gap of 217 vs OECD average 145 (confirming the behavioral/social failure is larger). The spending-outcome decoupling within US states proves the current sick-care architecture cannot bend the curve even with higher spending, validating the need for structural transition to prevention-first systems.
-
-
-## Supporting Evidence
-
-**Source:** CMS MSSP 2024 Performance Year Results, September 2025
-
-MSSP ACOs in 2024 generated $2.48B in net savings while simultaneously outperforming non-ACO peers on depression screening (53.53% vs 44.42%), blood pressure control (71.21% vs 67.82%), and cancer screening. This empirically demonstrates the prevention-first flywheel in practice: aligned payment creates incentives that improve both cost and quality simultaneously, with per capita savings accelerating from $207 to $241 year-over-year.

domains/health/value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk.md

@@ -1,13 +1,29 @@
 ---
-type: claim
-domain: health
-description: VBC adoption shows a wide gap between participation and risk-bearing with 60 percent of payments in value arrangements but only 14 percent in full capitation revealing that most providers take upside bonuses without accepting downside risk
 confidence: likely
-source: HCP-LAN 2022-2025 measurement; IMO Health VBC Update June 2025; Grand View Research VBC market analysis; Larsson et al NEJM Catalyst 2022
 created: 2026-02-17
-related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "home-based-care-could-capture-265-billion-in-medicare-spending-by-2025-through-hospital-at-home-remote-monitoring-and-post-acute-shift", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months", "Does prevention-first care reduce total healthcare costs or just redistribute them from acute to chronic spending?", "attractor-molochian-exhaustion", "value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk"]
-related_claims: ["double-coverage-compression-simultaneous-medicaid-cuts-and-aptc-expiry-eliminate-coverage-for-under-400-fpl", "medicaid-work-requirements-cause-coverage-loss-through-procedural-churn-not-employment-screening", "upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure", "medically-tailored-meals-achieve-pharmacotherapy-scale-bp-reduction-in-food-insecure-hypertensive-patients", "hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022", "uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant"]
-reweave_edges: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31", "home-based-care-could-capture-265-billion-in-medicare-spending-by-2025-through-hospital-at-home-remote-monitoring-and-post-acute-shift|related|2026-03-31", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04", "Does prevention-first care reduce total healthcare costs or just redistribute them from acute to chronic spending?|related|2026-04-17"]
+description: VBC adoption shows a wide gap between participation and risk-bearing with 60 percent of payments in value arrangements but only 14 percent in full capitation revealing that most providers take
+  upside bonuses without accepting downside risk
+domain: health
+related:
+- federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings
+- home-based-care-could-capture-265-billion-in-medicare-spending-by-2025-through-hospital-at-home-remote-monitoring-and-post-acute-shift
+- GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months
+- Does prevention-first care reduce total healthcare costs or just redistribute them from acute to chronic spending?
+- attractor-molochian-exhaustion
+related_claims:
+- double-coverage-compression-simultaneous-medicaid-cuts-and-aptc-expiry-eliminate-coverage-for-under-400-fpl
+- medicaid-work-requirements-cause-coverage-loss-through-procedural-churn-not-employment-screening
+- upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure
+- medically-tailored-meals-achieve-pharmacotherapy-scale-bp-reduction-in-food-insecure-hypertensive-patients
+- hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022
+- uspstf-glp1-policy-gap-leaves-aca-mandatory-coverage-dormant
+reweave_edges:
+- federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31
+- home-based-care-could-capture-265-billion-in-medicare-spending-by-2025-through-hospital-at-home-remote-monitoring-and-post-acute-shift|related|2026-03-31
+- GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04
+- Does prevention-first care reduce total healthcare costs or just redistribute them from acute to chronic spending?|related|2026-04-17
+source: HCP-LAN 2022-2025 measurement; IMO Health VBC Update June 2025; Grand View Research VBC market analysis; Larsson et al NEJM Catalyst 2022
+type: claim
 ---
 
 # value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk
@@ -85,17 +101,4 @@ Relevant Notes:
 - [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]] -- the 86% of payments not at full risk are systematically ignoring the factors that matter most for health outcomes
 
 Topics:
-- health and wellness
-
-## Extending Evidence
-
-**Source:** CMS MSSP 2024 Performance Year Results, September 2025
-
-MSSP 2024 results show that within the program, 67% of ACOs now participate in downside risk tracks (Level E or Enhanced), generating $5.4B of $6.6B in gross savings. This demonstrates that where policy enables full risk-bearing, adoption is advancing rapidly—the 14% aggregate statistic reflects slow system-wide transition, not model failure. CMS 2026 rules making two-sided risk the default for new MSSP entrants further accelerate this shift.
-
-
-## Extending Evidence
-
-**Source:** HCPLAN 2024 Annual Survey, CMS 2026 final rule
-
-HCPLAN 2024 survey (282.9M covered lives, 92.7% of US insured) shows full capitation doubled from 7% (2021) to 14% (2024), with total downside risk APMs reaching 28.5%. CMS 2026 final rule makes two-sided risk the 'organizing principle' for Medicare payment. MSSP reducing one-sided risk period from 7 to 5 years starting 2027. Trump administration actively pushing for MORE downside risk adoption to generate Medicare savings. The transition is accelerating: 4-year doubling rate with bipartisan federal policy support, though absolute penetration remains low.
+- health and wellness

entities/health/health-care-payment-learning-action-network.md

@@ -1,19 +0,0 @@
-# Health Care Payment Learning & Action Network (HCPLAN)
-
-**Type:** Multi-stakeholder collaborative
-**Focus:** Alternative payment model (APM) adoption measurement and acceleration
-**Coverage:** Annual survey tracking ~93% of US insured population
-
-## Overview
-
-HCPLAN is the authoritative source for measuring value-based care adoption in US healthcare. Their annual survey tracks payment model distribution across commercial insurance, Medicare, and Medicaid.
-
-## Methodology
-
-- **2024 survey:** 73 health plans, 4 FFS Medicaid states, Traditional Medicare
-- **Coverage:** 282.9 million lives (92.7% of all insured Americans)
-- **Categories:** 4-tier APM classification from FFS (Category 1) to full capitation (Category 4)
-
-## Timeline
-
-- **2024-09-01** — Published 2024 annual survey showing full capitation doubled to 14%, total downside risk at 28.5%

entities/health/waltz-health.md

@@ -1,26 +0,0 @@
-# Waltz Health
-
-**Type:** Healthcare access platform  
-**Domain:** GLP-1 direct-to-employer distribution  
-**Status:** Active (as of 2026-01)
-
-## Overview
-
-Waltz Health operates a direct-to-employer (DTE) access program for FDA-approved obesity medications, partnering with Novo Nordisk to bypass traditional PBM intermediation.
-
-## Timeline
-
-- **2026-01-01** — Launched DTE access program for FDA-approved obesity medications in partnership with Novo Nordisk
-
-## Business Model
-
-DTE channel for GLP-1 access, competing with traditional PBM distribution. No enrollment data or market penetration disclosed as of Q1 2026.
-
-## Market Position
-
-Part of the emerging manufacturer-direct distribution strategy alongside Eli Lilly's Employer Connect and 9amHealth's No-Barriers Bundle. Expert consensus characterizes DTE as 'incremental governance shift, not structural PBM displacement.'
-
-## Sources
-
-- HR Brew, December 2025
-- PR Newswire, January 2026

inbox/archive/health/2026-04-29-9amhealth-waltz-novo-dte-glp1-access-2026.md

@@ -1,71 +0,0 @@
----
-type: source
-title: "Novo Nordisk / 9amHealth No-Barriers Bundle and Waltz Health DTE Channel: GLP-1 Access Architecture Evolving"
-author: "HR Brew / BioxConomy / PR Newswire"
-url: https://www.hr-brew.com/stories/2025/12/19/eli-lilly-novo-nordisk-direct-to-employer
-date: 2025-12-19
-domain: health
-secondary_domains: []
-format: article
-status: processed
-processed_by: vida
-processed_date: 2026-04-29
-priority: medium
-tags: [GLP-1, direct-to-employer, Novo-Nordisk, 9amHealth, Waltz-Health, access, DTE, employer-benefits]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-**The DTE GLP-1 landscape as of Q4 2025 – Q1 2026:**
-
-**Novo Nordisk approach:**
-- Partnership with 9amHealth (August 2025): specialist-led virtual clinic for obesity care through NovoCare.com
-- Waltz Health: DTE access program for FDA-approved obesity medications, launched January 1, 2026
-- 9amHealth No-Barriers Bundle: integrates access to FDA-approved obesity medications from BOTH Eli Lilly and Novo Nordisk at fixed monthly costs
-- 9amHealth in discussions with employer groups, anticipates first partnerships "in early 2026"
-
-**Novo Nordisk vs. Eli Lilly positioning:**
-- Eli Lilly forecasting 25% revenue growth 2026 despite price pressure
-- Novo Nordisk warned: 5-13% sales decline in 2026 due to price falls in US + exclusivity expiry in China/Brazil/Canada
-- Lilly gaining market share as Novo faces challenges; NVO climbing toward $41 as of April 2026 (recovery)
-
-**GLP-1 utilization data:**
-- Share of respondents using GLP-1s has "more than doubled since 2023, reaching 49%" — NOTE: this likely refers to a specific surveyed population (likely employer benefits survey), not general population. General population prevalence is lower.
-
-**Cost vs. access tension:**
-- 49% GLP-1 usage growth among surveyed populations vs. 22% decline in covered lives (3.6M → 2.8M)
-- Higher utilization among those who maintain coverage + higher costs driving coverage withdrawal among health systems and regional payers
-
-**DTE model assessment:**
-- Both manufacturers (Lilly, Novo) now competing via DTE alongside traditional PBM channels
-- But: neither has disclosed enrollment data or market penetration
-- Expert consensus: incremental governance shift, not structural PBM displacement
-- "Manufacturers positioning themselves as more active participants in employer access strategy"
-
-## Agent Notes
-
-**Why this matters:** Provides full picture of the GLP-1 DTE access architecture evolution. Both major GLP-1 manufacturers (Lilly, Novo) are now pursuing DTE channels, but DTE remains incremental. Critical context: Novo is facing financial pressure (sales decline warning) while Lilly grows — this market structure divergence may accelerate Lilly's DTE as differentiation strategy.
-
-**What surprised me:** The Novo Nordisk 5-13% sales decline warning for 2026 was not in the KB. Given Ozempic/Wegovy's dominant brand recognition, the revenue decline suggests the GLP-1 market is more competitive and price-pressured than the "largest therapeutic category launch in history" narrative implied. Lilly's Zepbound (tirzepatide) appears to be winning the clinical competition through DTE access and efficacy data.
-
-**What I expected but didn't find:** Enrollment data for the DTE programs. Neither Lilly, Novo, 9amHealth, nor Waltz Health has disclosed how many employers have enrolled or how many covered lives are in DTE channels. The lack of scale data makes it impossible to assess whether DTE is material or marginal.
-
-**KB connections:**
-- Relates to [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — the market is becoming more fragmented and price-competitive than this claim's framing
-- Connects to the employer coverage crisis archive (3.6M → 2.8M decline) — utilization vs. coverage divergence
-- Connects to [[value-based care transitions stall at the payment boundary]] — DTE doesn't change payment incentives
-
-**Extraction hints:**
-- NOT ready for standalone extraction — DTE architecture is too early and unscaled for a knowledge claim
-- ENRICHMENT: The existing GLP-1 claim should note the competitive market structure (Lilly gaining, Novo declining, DTE emerging) as context for the "inflationary through 2035" trajectory
-- WATCH: Track DTE enrollment data in future sessions — if DTE achieves meaningful scale (>1M covered lives), it becomes a legitimate claim about distribution disruption
-
-**Context:** Multiple December 2025 sources (HR Brew DTE launch announcement). 9amHealth No-Barriers Bundle launched early 2026. BioxConomy analysis. Represents the access architecture state as of Q1 2026.
-
-## Curator Notes
-
-PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
-WHY ARCHIVED: DTE architecture context for GLP-1 access story. Also: Novo Nordisk 5-13% sales decline warning is a new data point suggesting competitive market pressure not captured in KB. Monitor but not ready for standalone extraction.
-EXTRACTION HINT: Note the utilization/coverage divergence — usage up among those who have coverage, total covered lives declining. These are compatible but the net population-level access picture is worsening.

inbox/archive/health/2026-04-29-cms-mssp-py2024-2-4b-savings-vbc-structural-proof.md

@@ -1,69 +0,0 @@
----
-type: source
-title: "CMS Medicare Shared Savings Program: 2024 Performance Year Financial and Quality Results — Record $2.48B Net Savings"
-author: "Centers for Medicare & Medicaid Services"
-url: https://accountableforhealth.org/accountability-delivered-in-medicare-shared-savings-program-results-from-2024/
-date: 2025-09-09
-domain: health
-secondary_domains: []
-format: report
-status: processed
-processed_by: vida
-processed_date: 2026-04-29
-priority: high
-tags: [value-based-care, ACO, MSSP, CMS, payment-reform, structural-fix, belief-3]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-CMS released performance year 2024 results for the Medicare Shared Savings Program (MSSP). Key findings:
-
-**Financial performance:**
-- Net Medicare savings: $2.48 billion — record, 8th consecutive year of net savings
-- Gross savings (before shared savings payments): $6.6 billion total
-- 75% of ACOs earned shared savings, receiving $4.1 billion in performance payments
-- Per capita net savings: $241 (up $34 from 2023)
-- Per capita gross savings: $643 (up $128 from 2023)
-
-**Risk track distribution:**
-- Two-thirds of ACOs participating in Level E or Enhanced (downside risk) tracks
-- ACOs in Level E and Enhanced generated more than two-thirds of all savings ($5.4B of $6.6B gross)
-
-**Quality metrics:**
-- Nearly every ACO met CMS quality standards — continuing a decade-long trend
-- ACOs outperformed non-ACO physician groups on:
-  - Screening for Depression and Follow-up Plan: 53.53% (ACO) vs 44.42% (non-ACO)
-  - Controlling High Blood Pressure: 71.21% vs 67.82%
-- Improved performance on A1c control, cancer screening
-
-**Enrollment context:**
-- Total MSSP ACO enrollment growing year-over-year
-- CMS 2026 rule making two-sided risk the default: new Ambulatory Specialty Model (ASM) for heart failure and low back pain, restricting one-sided MSSP participation
-
-## Agent Notes
-
-**Why this matters:** This is the empirical proof that value-based care's structural fix thesis (Belief 3) actually works at scale. $2.48B in net annual savings is not aspirational — it's measured, audited, and eighth-year consecutive. This is the strongest single piece of evidence in the KB that VBC is more than policy proposal.
-
-**What surprised me:** The quality improvement alongside cost reduction. The classic critique of VBC is that it will cut costs by under-treating patients. The ACO data shows the opposite — ACOs outperform peers on depression screening, BP control, cancer screening WHILE generating $2.48B in savings. Cost and quality are moving together.
-
-**What I expected but didn't find:** Any evidence of MSSP performance deteriorating. Given the MA disruptions (CMS tightening, UHG losses, Humana exits), I expected MSSP to show similar stress. Instead it's accelerating.
-
-**KB connections:**
-- Directly confirms [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] — this is the state of the TRANSITION, not proof VBC doesn't work
-- Directly supports Belief 3: "Value-based care is the structural fix, but transition is slow"
-- Connects to [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]]
-
-**Extraction hints:**
-- PRIMARY: "MSSP ACOs generated record $2.48B in net Medicare savings in 2024 for the eighth consecutive year, while maintaining superior quality performance compared to non-ACO peers — empirically confirming that cost and quality improvement are achievable simultaneously under value-based payment"
-- SECONDARY: Two-thirds of MSSP ACOs now in downside risk tracks — the transition IS advancing despite slow aggregate payment statistics
-- The per capita savings growth ($34 more in net, $128 more in gross vs. 2023) shows acceleration, not stagnation
-
-**Context:** Released September 2025. Most recent publicly available MSSP performance data. CMS simultaneously issued 2026 rules expanding mandatory risk-bearing — the structural direction is accelerating.
-
-## Curator Notes
-
-PRIMARY CONNECTION: [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
-WHY ARCHIVED: Belief 3 disconfirmation target — does VBC structural fix actually work? This is the strongest empirical answer: record $2.48B savings, 8th consecutive year, quality improving alongside costs. Disconfirmation FAILS — Belief 3 confirmed.
-EXTRACTION HINT: Focus on the cost-quality co-improvement (defeats the under-treatment critique) and the acceleration of downside risk adoption (2/3 of ACOs now in downside risk). Two claims, not one.

inbox/archive/health/2026-04-29-employer-glp1-coverage-crisis-enrollment-declining-2026.md

@@ -1,74 +0,0 @@
----
-type: source
-title: "Employers' Growing GLP-1 Coverage Crisis: Enrolled Lives Dropped from 3.6M to 2.8M as Health Systems and Insurers Withdraw"
-author: "DistilINFO Publications"
-url: https://distilinfo.com/2026/04/28/employers-growing-glp-1-coverage-crisis/
-date: 2026-04-28
-domain: health
-secondary_domains: []
-format: article
-status: processed
-processed_by: vida
-processed_date: 2026-04-29
-priority: high
-tags: [GLP-1, employer-coverage, cost-crisis, health-systems, coverage-withdrawal, obesity, adherence]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-Published April 28, 2026 (yesterday), citing December 2025 analysis from Leverage|Axiaci:
-
-**GLP-1 weight-loss coverage DECLINING:**
-- Covered individuals enrolled in GLP-1 weight-loss coverage: 3.6 million (2024) → 2.8 million (2026)
-- A net DECREASE in covered lives while overall GLP-1 utilization is rising
-
-**Major health system withdrawals:**
-- Allina Health, RWJBarnabas Health, Ascension, Hennepin Healthcare: discontinued coverage entirely
-- Fairview Health Services: targeted $10M+ savings through restrictions
-- Kaiser Permanente: cut California commercial and ACA member coverage (early 2025)
-- Mass General Brigham Health Plan: ended coverage for small employers and individual members
-
-**Insurance cost crisis:**
-- Blue Cross Blue Shield Michigan: "$350 million increase in GLP-1 drug costs in 2023 alone"
-- Blue Cross Blue Shield Massachusetts: "$400 million operating loss in 2024, driven largely by GLP-1 spending"
-
-**State employee plan withdrawals:**
-- Ohio, Idaho, Louisiana, Massachusetts: don't cover weight-loss GLP-1s for state employees
-- (Note: four additional states vs. what may have been in previous KB)
-
-**Counter-evidence: payer mandate story challenged:**
-- Session 30 (April 28) found: 34% of employers now REQUIRE behavioral support as GLP-1 coverage condition (up from 10%)
-- This data shows: total covered lives are DECLINING even as coverage conditions tighten
-- The two trends are compatible: employers who keep coverage are adding behavioral mandates, but more employers are DROPPING coverage entirely
-
-**Alternative approaches demonstrating ROI:**
-- Jefferson Health lifestyle intervention program: saved $20 million with 90% participant engagement
-- Non-pharmaceutical interventions being tested as GLP-1 alternatives due to cost pressures
-
-## Agent Notes
-
-**Why this matters:** This directly challenges the "payer mandate acceleration" story from Session 30. Session 30 found that 34% of employers now require behavioral support (up from 10%) — suggesting coverage is expanding with conditions. This data shows total COVERED LIVES are declining 22% from 2024 to 2026. These two can coexist — employers who keep coverage add behavioral gates while others drop coverage — but the net access picture is WORSE, not better.
-
-**What surprised me:** The BCBS Massachusetts $400M operating loss driven by GLP-1 spending. This is an insurer with broad population coverage (not just large employers) taking extraordinary losses. If this dynamic is occurring at major regional Blues plans, the economics are much worse than the "inflationary through 2035" KB claim implies — it may be causing structural retreat from coverage, not just cost pressure.
-
-**What I expected but didn't find:** Evidence that payer managed-access systems (Evernorth, UHC Total Weight Support) are partially offsetting the coverage withdrawal. The coverage crisis article doesn't mention managed-access platforms from Session 30 research — may be that managed-access is a large-employer story while coverage withdrawal is concentrated among mid-market and regional payers.
-
-**KB connections:**
-- Challenges: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — the "inflationary" prediction appears to be proving correct, but the system response (coverage withdrawal) is not captured in the claim
-- Challenges: The payer mandate acceleration story (PHTI December 2025, 34% employers requiring behavioral support) — the behavioral mandate story is for employers who keep coverage; many are dropping
-- Connects to [[value-based care transitions stall at the payment boundary]] — cost pressure from GLP-1s is creating coverage-access gaps that VBC transition hasn't addressed
-
-**Extraction hints:**
-- CLAIM: "GLP-1 weight-loss drug coverage is declining at the employer and health system level — enrolled lives dropped 22% from 3.6M (2024) to 2.8M (2026) — as cost pressures exceed VBC cost management capacity, creating a widening access gap for populations with highest clinical need"
-- ENRICHMENT: The existing GLP-1 KB claim should be challenged_by this access decline data — "inflationary through 2035" is true, but the system response (coverage withdrawal) creates an access-gap dimension not captured in the cost trajectory claim
-- SCOPE QUALIFICATION needed: The "payer mandate acceleration" (behavioral support as condition) story and the "coverage withdrawal" story are about different payer segments — large sophisticated employers vs. regional/mid-market payers and health systems. The KB needs to capture both.
-
-**Context:** DistilINFO citing Leverage|Axiaci December 2025 analysis. Most recent employer coverage data available. The 3.6M → 2.8M figure is for weight-loss indication specifically (not diabetes GLP-1 coverage, which is different).
-
-## Curator Notes
-
-PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
-WHY ARCHIVED: Critical counterpoint to Session 30's payer mandate acceleration story. Coverage withdrawal (3.6M → 2.8M covered lives) challenges the "expanding access" narrative. Creates a divergence candidate with the behavioral mandate data.
-EXTRACTION HINT: Check for divergence: (a) Session 30 archives show payer behavioral mandate acceleration, (b) this shows total covered lives declining. These may be a scope mismatch (large employers vs. mid-market) or genuine divergence. Extractor should check both bodies of evidence carefully.

inbox/archive/health/2026-04-29-hcplan-2024-vbc-full-risk-doubled-28pct-downside.md

@@ -1,66 +0,0 @@
----
-type: source
-title: "HCPLAN 2024 Annual Survey: Full Capitation Doubled to 14%, 28.5% of Payments in Downside Risk APMs"
-author: "Health Care Payment Learning & Action Network (HCPLAN)"
-url: https://hcp-lan.org/2024-infographic/
-date: 2025-09-01
-domain: health
-secondary_domains: []
-format: report
-status: processed
-processed_by: vida
-processed_date: 2026-04-29
-priority: high
-tags: [value-based-care, payment-reform, full-risk, capitation, downside-risk, APM, HCPLAN, belief-3]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-The Health Care Payment Learning & Action Network (HCPLAN) 2024 annual survey measured APM adoption across 73 health plans, 4 FFS Medicaid states, and Traditional Medicare — representing 282.9 million covered lives (92.7% of all insured Americans).
-
-**Key statistics:**
-- **Full capitation (Category 4):** ~14% of all US healthcare payments — DOUBLED from 7% in 2021 (4-year timeframe)
-- **Downside risk APMs (Category 3+4):** 28.5% of US healthcare payments — up from 24.5% in 2022
-- **Accountable care arrangements:** 88.5 million lives in Categories 3+4 combined
-
-**Trend context (from broader research sources):**
-- 2021: 7% fully capitated
-- 2022: 24.5% in downside risk
-- 2024: 14% fully capitated, 28.5% in downside risk
-- CMS 2030 goal: all Medicare FFS beneficiaries in accountable care relationship
-
-**CMS policy acceleration:**
-- 2026 final rule: making two-sided risk the "organizing principle" for Medicare payment
-- New mandatory Ambulatory Specialty Model (ASM): heart failure and low back pain
-- MSSP: reducing time allowed in one-sided risk from 7 to 5 years (starting 2027)
-- REACH Model: full risk option — 100% of savings or losses
-
-**Trump administration position:** Supporting ACO expansion and pushing for MORE downside risk adoption to generate savings from MSSP programs.
-
-## Agent Notes
-
-**Why this matters:** Provides the quantitative trend line for VBC structural transition — the core measure of whether Belief 3's "transition is slow but real" is tracking correctly. Full capitation DOUBLING in 4 years (7% → 14%) is more meaningful than the absolute 14% figure.
-
-**What surprised me:** The Trump administration's PRO-VBC stance. The KB narrative has been that VBC transition faces political headwinds, but the Trump administration is actively pushing for MORE downside risk adoption to generate Medicare savings. The structural transition has bipartisan momentum at the federal level.
-
-**What I expected but didn't find:** Evidence that the MA market disruptions (UHG losses, Humana exits from markets) are slowing the broader VBC trend. The HCPLAN data covers ALL insurance, not just MA — so the MA distress doesn't dominate the overall picture.
-
-**KB connections:**
-- Directly measures the transition described in [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]] — the 14% full-risk figure is now updated (14% capitated, 28.5% downside risk)
-- The ~50% full-risk threshold mentioned in Vida's identity.md as the tipping point is still far, but doubling in 4 years shows credible trajectory
-- Connects to [[the healthcare attractor state is a prevention-first system...]] — this is the mechanism of transition toward that attractor
-
-**Extraction hints:**
-- UPDATE CLAIM: The existing "14 percent bear full risk" figure needs updating — it's now 14% FULLY CAPITATED (up from 7% in 2021), with 28.5% in any downside risk APM. The original claim's framing ("only 14 percent bear full risk") is still roughly accurate numerically but the trend direction matters: it has doubled.
-- NEW CLAIM: "Full capitation in US healthcare doubled from 7% to 14% between 2021-2025, with CMS policy actively accelerating the shift to two-sided risk as the default payment model — suggesting the VBC structural transition is accelerating despite its slow absolute pace"
-- The absolute/relative tension: 14% full-risk is still low in absolute terms but the doubling rate and CMS policy direction suggest it's not stagnating.
-
-**Context:** HCPLAN measures the broadest available population (92.7% of covered lives). Most authoritative VBC adoption data in the field. Annual survey, 2024 results.
-
-## Curator Notes
-
-PRIMARY CONNECTION: [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
-WHY ARCHIVED: Provides updated quantitative data for the VBC adoption rate claim. The existing claim should be enriched with trend data (7% → 14% doubling). CMS policy acceleration is the structural driver.
-EXTRACTION HINT: Two extraction opportunities: (1) enriching the existing VBC transition claim with updated trend data, and (2) potentially a new claim about the VBC transition acceleration rate and CMS policy direction.

inbox/archive/health/2026-04-29-lilly-employer-connect-not-revolutionary-dte-limits.md

@@ -1,72 +0,0 @@
----
-type: source
-title: "Lilly Employer Connect Adds Flexibility for Employers But Isn't Revolutionary, Expert Says"
-author: "MedCity News / Fierce Healthcare / Sequoia"
-url: https://medcitynews.com/2026/03/lilly-employers-glp1s/
-date: 2026-03-05
-domain: health
-secondary_domains: []
-format: article
-status: processed
-processed_by: vida
-processed_date: 2026-04-29
-priority: medium
-tags: [GLP-1, direct-to-employer, DTE, PBM, Lilly, employer-coverage, market-competition]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-Eli Lilly launched Employer Connect on March 5, 2026 — a direct-to-employer platform offering Zepbound at $449/month net price (vs. $1,000+ retail) through 18 program administrators. Key expert assessments:
-
-**MedCity News / National Alliance of Healthcare Purchaser Coalitions expert:**
-- "This isn't revolutionary, but it shows incremental improvements in flexibility for employers seeking to provide access for these expensive drugs."
-- Pricing "doesn't appear to be substantially lower than the price employers were already getting" through existing channels
-- No enrollment projections, adoption targets, or enrollment data provided by Lilly
-
-**Sequoia governance analysis (April 2026):**
-- "This isn't primarily a pricing story. It's a control and governance story."
-- Historically: manufacturers influenced access indirectly through PBMs. Now Lilly is direct participant in employer strategy
-- Introduces new complexity in cost oversight, vendor alignment, and long-term financial accountability
-- Fundamentally shifts how employers engage with drug manufacturers
-
-**Market structure context:**
-- Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) still control approximately 80% of U.S. prescription claims
-- Cost Plus Drugs remains marginal challenger despite growth; partnering WITH Humana CenterWell rather than displacing incumbents
-- 18 administrator partners include: Calibrate, Form Health, Waltz Health, GoodRx — behavioral integration layer, not simple drug delivery
-
-**Coverage landscape:**
-- Only 20% of companies with 200+ workers cover weight loss drugs
-- Only 43% of companies with 5,000+ employees cover weight loss drugs
-- Lilly forecasting 25% revenue growth for 2026 (from all sources, not DTE alone)
-
-**Price transparency parallel (from broader research):**
-- Hospital price transparency rules show limited impact on insured patients
-- Consumer price pressure limited to self-pay elective procedures only
-- Insured patients (the majority) show no behavioral changes from price transparency
-
-## Agent Notes
-
-**Why this matters:** Tests whether market competition mechanisms (DTE, Cost Plus, price transparency) can bypass structural payment misalignment without VBC reform — the core Belief 3 disconfirmation scenario. The "not revolutionary" assessment from the National Alliance expert is the key verdict.
-
-**What surprised me:** Lilly's $449/month price is NOT substantially cheaper than what employers were already getting through rebate structures. The headline price cut ($449 vs. $1,000 list) is misleading — employers with PBM rebate contracts were already at comparable net prices. The DTE story is about GOVERNANCE SHIFT, not price disruption.
-
-**What I expected but didn't find:** Enrollment data, adoption targets, any evidence of scale. Lilly provided none. The DTE channel is launching but has no demonstrated scale yet.
-
-**KB connections:**
-- Connects to [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — DTE reduces list price but doesn't change the chronic use economics
-- Connects to [[value-based care transitions stall at the payment boundary]] — DTE is a distribution innovation, not a payment model change; FFS incentive structure persists
-
-**Extraction hints:**
-- CLAIM: "Manufacturer direct-to-employer GLP-1 channels represent a governance shift rather than structural disruption — the $449 DTE price is not substantially below existing PBM net prices, and Big Three PBMs still control 80% of US prescription claims"
-- COMPLICATION: The Sequoia "control and governance" framing suggests DTE may be more significant long-term (manufacturers as active participants in employer benefit design)
-- SCOPE: This is about drug pricing/distribution channels, not about the FFS payment model that Belief 3 describes. DTE doesn't change how hospitals or physicians are paid.
-
-**Context:** Lilly launch announcement March 5, 2026. MedCity expert assessment same week. Sequoia governance analysis April 2026. Represents the state of "market competition as structural bypass" in Q1-Q2 2026.
-
-## Curator Notes
-
-PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
-WHY ARCHIVED: Direct evidence for Belief 3 disconfirmation attempt — does market competition bypass structural misalignment? Answer: no. DTE is incremental governance shift, not structural disruption. PBMs control 80% of claims. Price transparency is limited to self-pay.
-EXTRACTION HINT: Extractor should distinguish between the two market competition arguments: (1) drug pricing channels (DTE, Cost Plus) vs. (2) healthcare payment model (FFS vs. VBC). They're separate layers. DTE disrupts drug distribution slightly but doesn't touch FFS payment incentives.

inbox/archive/health/2026-04-29-mhpaea-fourth-report-2025-enforcement-structural-limits.md

@@ -1,78 +0,0 @@
----
-type: source
-title: "2025 MHPAEA Report to Congress: Enforcement Structural Limits — Payers Build Medical Networks But Not Mental Health Networks"
-author: "DOL / HHS / Treasury + EBSA OIG"
-url: https://beta.dol.gov/research-data/report/2025-mhpaea-report-congress
-date: 2026-03-03
-domain: health
-secondary_domains: []
-format: report
-status: processed
-processed_by: vida
-processed_date: 2026-04-29
-priority: high
-tags: [mental-health, MHPAEA, parity, enforcement, supply-gap, workforce, network-adequacy]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-The 4th annual MHPAEA (Mental Health Parity and Addiction Equity Act) Report to Congress was published March 3, 2026, covering August 2023 – July 2025 enforcement period.
-
-**Key compliance gaps identified:**
-
-**Network adequacy — the structural mechanism:**
-- EBSA found multiple instances where plan sponsors/issuers "actively increased reimbursement rates for certain M/S [medical/surgical] providers as a strategy to attract and retain service providers where they found insufficiency in the network"
-- **But the same methodologies were NOT utilized to attract and retain MH/SUD providers, even where gaps were identified in MH/SUD provider networks**
-- This is the structural mechanism: payers are WILLING to raise reimbursement to fix medical network gaps but NOT applying the same approach for mental health gaps
-
-**NQTL Documentation Deficiencies:**
-- Plans and issuers failed to provide adequate comparative analyses demonstrating Nonquantitative Treatment Limitation (NQTL) compliance
-- Prior authorization for MH/SUD more stringent than equivalent medical/surgical services
-
-**Key exclusions found:**
-- Applied behavior analysis (ABA) therapy for autism spectrum disorder
-- Nutritional counseling for eating disorders
-- Medication-assisted treatment (MAT) for opioid use disorder
-
-**Enforcement posture shift:**
-- 2025 Report shows Trump administration is "not as active as they previously were in MHPAEA enforcement" at federal level
-- State enforcement is escalating as federal action contracts
-- EBSA OIG report: "EBSA Faced Challenges Enforcing Compliance with Mental Health Parity" — enforcement itself is undermined structurally
-
-**The compliance vs. access gap:**
-- Strong enforcement (2024 rule: new NQTL comparative analysis requirements, network adequacy standards, ABA/MAT exclusion coverage mandates)
-- But: covering more benefit types doesn't create more providers
-- DOL enforcement actions targeting network adequacy — "dozens" of actions, $100K-$2M+ penalties
-- Yet the supply shortage (too few therapists, reimbursement too low) persists regardless of compliance mandates
-
-**Independent academic analysis (Tandfonline 2025):**
-- "Can Mental Health Parity Be an Effective Tool to Challenge Inadequate Networks and Low Reimbursement Rates?"
-- Asks explicitly whether parity enforcement can address the structural supply constraint
-
-## Agent Notes
-
-**Why this matters:** Tests whether MHPAEA enforcement can close the "mental health supply gap widening" claim in the KB. The answer emerging from this report: enforcement fixes coverage mandates but doesn't create providers. The structural barrier (workforce shortage + reimbursement rates) persists independently of compliance mandates.
-
-**What surprised me:** The specific mechanism revealed by the EBSA report — payers are ACTIVELY raising reimbursement for medical networks but DELIBERATELY not applying the same methodology to mental health networks. This isn't ignorance or oversight — it's a documented structural choice that enforcement must directly address. This is the clearest articulation I've seen of why parity doesn't produce access.
-
-**What I expected but didn't find:** Evidence that the 2024-2025 enforcement push has produced measurable access improvements (reduced wait times, more in-network providers). The report focuses on compliance requirements and enforcement actions, not access outcome metrics. Absence of outcome data is informative.
-
-**KB connections:**
-- Directly connects to [[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]]
-- Adds new precision: the gap mechanism isn't just workforce shortage — it's also payers' differential treatment of MH vs medical reimbursement rates (documented, not inferred)
-- Connects to Belief 2 (80-90% of outcomes non-clinical): mental health is the most significant underfunded non-clinical determinant
-
-**Extraction hints:**
-- CLAIM CANDIDATE: "Mental health parity enforcement closes coverage gaps but cannot close the access gap because payers demonstrate structural differential treatment of mental health vs. medical reimbursement rates — paying more to attract medical providers but not applying the same methodology to mental health provider networks"
-- ENRICHMENT: The existing [[mental health supply gap is widening not closing...]] claim can be enriched with this mechanism: it's not just demand > supply — it's that payers are documented as actively NOT fixing the supply incentives
-- NOTE: The enforcement posture shift under Trump administration (less active federal, escalating state) is a policy fragility point.
-
-**Context:** 4th annual report, most recent available. Published March 2026. DOL OIG separate report on enforcement challenges. EBSA covers employer-sponsored plans; CMS covers Medicaid/ACA.
-
-## Curator Notes
-
-PRIMARY CONNECTION: [[the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access]]
-WHY ARCHIVED: Documents the structural mechanism explaining WHY enforcement doesn't close the access gap — payers differentially treat MH vs medical reimbursement. Strongest single piece of evidence for the structural mechanism underlying the supply gap claim.
-EXTRACTION HINT: The key extraction is the MECHANISM, not just the compliance failures. "Payers raise medical reimbursement to fix network gaps but don't apply same methodology to mental health" — this is a claim about structural incentive differential, not just regulatory non-compliance.

inbox/archive/health/2026-04-29-mssp-health-affairs-2024-aco-participation-trends.md

@@ -1,77 +0,0 @@
----
-type: source
-title: "Medicare ACOs In 2024: Increased Participation and Evolving Policy Impacts — Health Affairs"
-author: "Health Affairs Forefront"
-url: https://www.healthaffairs.org/do/10.1377/forefront.20251105.540959/
-date: 2025-11-05
-domain: health
-secondary_domains: []
-format: article
-status: processed
-processed_by: vida
-processed_date: 2026-04-29
-priority: medium
-tags: [ACO, MSSP, Medicare, value-based-care, policy, downside-risk, 2024]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-Health Affairs analysis of MSSP 2024 performance year results:
-
-**Participation trends:**
-- Increased ACO participation in 2024 (enrollment growing)
-- Policy evolution: CMS 2026 rules restricting one-sided participation (reducing one-sided MSSP cap from 7 to 5 years starting 2027)
-- New mandatory Ambulatory Specialty Model (ASM) for heart failure and low back pain
-
-**Financial performance (from CMS data):**
-- $2.48 billion net savings — record, 8th consecutive year
-- $6.6 billion gross savings
-- $641 per capita gross savings (up $128 from 2023)
-- $241 per capita net savings (up $34 from 2023)
-- Acceleration in per capita savings suggests quality improvement is compounding
-
-**Risk distribution:**
-- 2/3 of ACOs now in Level E or Enhanced (downside risk)
-- Level E + Enhanced generated $5.4B of $6.6B gross savings (82%)
-- The shift to downside risk is accelerating performance
-
-**Quality metrics:**
-- ACOs outperforming non-ACO peers on depression screening (53.5% vs 44.4%), BP control (71.2% vs 67.8%)
-- Blood pressure, A1c control, cancer screening all improving
-- NO quality-cost tradeoff observed — quality improving WITH cost reduction
-
-**Policy context:**
-- CMS 2026 "Transforming Episode Accountability Model" (TEAM) — new episode-based payment models
-- Trump administration priorities: maximize ACO savings by pushing downside risk
-- CMS Innovation Center refocusing on scalable APMs rather than new pilot programs
-
-**Privia Health subsidiary data:**
-- Privia ACOs: $233M+ total savings in 2024 performance year — 32% year-over-year increase
-
-## Agent Notes
-
-**Why this matters:** Provides detailed analysis framing around the headline $2.48B MSSP savings number. The Health Affairs framing is important: it's not just that VBC saves money, but that performance is accelerating and risk adoption is growing. The two-thirds of ACOs in downside risk is the structural shift — these are organizations BETTING on their ability to keep people healthy.
-
-**What surprised me:** The acceleration in per capita savings ($34 more net, $128 more gross vs. 2023). If per capita savings are growing each year, the MSSP model is exhibiting learning curve effects — ACOs are getting better at VBC over time. This is the compounding dynamic that the KB's attractor state model predicts.
-
-**What I expected but didn't find:** Evidence of ACO quality tradeoffs. The classic concern about capitated/at-risk models is they'll under-treat complex patients to avoid costs. The data shows the opposite — ACOs improve on depression screening, BP control, cancer screening at the same time they reduce costs. This is the aligned incentive model working as designed.
-
-**KB connections:**
-- Directly confirms [[the healthcare attractor state is a prevention-first system where aligned payment continuous monitoring and AI-augmented care delivery create a flywheel that profits from health rather than sickness]] — the ACO flywheel is empirically observable in 8-year data
-- Confirms Belief 3: structural fix (VBC) is working, not just aspirational
-- Connects to [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening]] — the ACO data is the broader VBC evidence base that Devoted operates within
-
-**Extraction hints:**
-- ENRICHMENT: Enrich existing VBC transition claim with acceleration data — per capita savings are growing, 2/3 of ACOs in downside risk, quality improving alongside cost reduction
-- CLAIM: "Medicare Shared Savings ACOs that moved to downside risk (Level E/Enhanced) generated 82% of total MSSP gross savings while representing two-thirds of participants — empirically demonstrating that aligned financial risk produces superior VBC performance to one-sided arrangements"
-- NEW PRECISION: The quality-cost co-improvement data (depression screening up 9pp, BP control up 3pp while generating record savings) is the strongest counter to the "VBC under-treats to cut costs" concern
-
-**Context:** Health Affairs Forefront, published November 2025. Leading health policy journal. Considered authoritative for VBC policy analysis.
-
-## Curator Notes
-
-PRIMARY CONNECTION: [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
-WHY ARCHIVED: Provides the qualitative framing and acceleration evidence missing from the raw CMS fact sheet. The "two-thirds in downside risk generating 82% of savings" is a specific claim candidate about risk-bearing ACOs as the high-performance tier.
-EXTRACTION HINT: The risk stratification finding is the key insight — two-thirds of ACOs in downside risk generating 82% of savings creates a precise, claimable assertion about how financial risk shapes VBC performance.

inbox/archive/health/2026-04-29-price-transparency-limited-insured-market-impact-2025.md

@@ -1,72 +0,0 @@
----
-type: source
-title: "Hospital Price Transparency 2025: Limited Market Impact for Insured Patients, Selective Effect for Self-Pay Elective Procedures"
-author: "Multiple sources: Mathematica, SAGE Journals, Brookings, CMS"
-url: https://journals.sagepub.com/doi/10.1177/10591478251367520
-date: 2025-01-01
-domain: health
-secondary_domains: []
-format: research
-status: processed
-processed_by: vida
-processed_date: 2026-04-29
-priority: medium
-tags: [price-transparency, market-competition, healthcare-costs, consumer-behavior, structural-reform]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-Aggregated from multiple 2025 sources on hospital price transparency compliance and market impact:
-
-**Compliance status (2025):**
-- 55% of 3,558 Medicare-certified general acute care hospitals had NOT posted readable commercial negotiated price files 6 months after rule took effect
-- 2025: additional requirements to publish estimated actual payment (allowed) amounts
-- Trump executive order February 25, 2025: new requirements for price transparency within 90 days
-
-**Market impact on consumer behavior (Pan & Yaraghi, SAGE 2025):**
-- Does NOT broadly reduce hospital charges
-- DOES lead to lower charges for self-pay patients opting for elective procedures who are sensitive to price and can shop
-- "Behavioral changes were NOT observed for insured patients"
-- Reason: insured patients insulated from full cost; less flexibility in provider choice
-
-**Theoretical upside (Brookings):**
-- Using 40% reduction in "shoppable" service expenditures: potential impact as high as $80.1 billion for commercial population
-- But this assumes significant behavioral change that hasn't materialized for insured patients
-
-**Why insured patients don't respond:**
-- Insured patients typically owe copay/deductible, not full price — price transparency doesn't change their marginal cost
-- Provider networks (HMO, narrow network plans) limit patient choice regardless of price knowledge
-- Emergency care, specialist referrals, surgery — not "shoppable" in the consumer sense
-
-**Context — Belief 3 implications:**
-- Market competition via price transparency is structurally limited to self-pay, elective, "shoppable" care — a minority of total healthcare spending
-- The majority of healthcare spending (insurance-mediated, emergency, specialist, inpatient) is structurally non-competitive regardless of price disclosure
-- FFS payment incentives operate at the payer-provider level, not the consumer level — price transparency doesn't touch this layer
-
-## Agent Notes
-
-**Why this matters:** Tests the "market competition bypasses structural misalignment" counter-argument to Belief 3. Price transparency is the most cited mechanism for consumer-driven healthcare cost reduction. The evidence: limited to self-pay elective procedures. The majority of healthcare spending is structurally insulated from consumer price pressure.
-
-**What surprised me:** The 55% hospital non-compliance rate even in 2025, years after the rule. Hospitals are actively resisting transparency despite the legal mandate. This is the proxy inertia prediction playing out in real time — financially successful institutions are not voluntarily enabling competitive pressure.
-
-**What I expected but didn't find:** Any evidence that transparency rules are producing systematic price competition between hospitals. Even where data is available, the evidence shows no broad charge reduction for insured patients.
-
-**KB connections:**
-- Confirms [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]] — hospitals are resisting transparency
-- Supports Belief 3: market mechanisms (price transparency) don't restructure FFS incentives
-- Connects to [[optimization for efficiency without regard for resilience creates systemic fragility...]] — the FFS system optimizes against the mechanisms intended to discipline it
-
-**Extraction hints:**
-- CLAIM: "Hospital price transparency rules produce measurable cost reductions only for self-pay patients seeking elective procedures — insured patients (the majority) show no behavioral change because insurance insulates them from marginal cost, leaving the FFS payment structure that determines provider incentives unchanged"
-- This is a scope-qualified claim about where market competition WORKS (self-pay elective) vs. where it DOESN'T (the majority of spending)
-- Confidence level: likely (confirmed by multiple independent studies)
-
-**Context:** Multiple 2025 sources synthesized. The Brookings piece is broadly cited. The Pan & Yaraghi SAGE paper is the most rigorous empirical analysis. CMS requirements still evolving.
-
-## Curator Notes
-
-PRIMARY CONNECTION: [[proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures]]
-WHY ARCHIVED: Documents the limits of market competition as structural bypass for healthcare misalignment — price transparency doesn't touch FFS payment incentives, and insured patients (majority) don't respond to price signals. Directly relevant to Belief 3 disconfirmation attempt.
-EXTRACTION HINT: Focus on the scope qualification: transparency works for self-pay elective procedures only. Insured care (the majority) is structurally insulated. This makes market competition a marginal mechanism, not a structural bypass.

inbox/archive/health/2026-04-29-ww-rebirth-clinical-transformation-no-cgm-belief4-generativity.md

@@ -1,81 +0,0 @@
----
-type: source
-title: "The WeightWatchers Rebirth: A Clinical Transformation and the GLP-1 Era — Post-Bankruptcy Strategy Without CGM Integration"
-author: "PredictStreet / FinancialContent"
-url: https://markets.financialcontent.com/stocks/article/predictstreet-2026-1-9-the-weightwatchers-rebirth-a-clinical-transformation-and-the-glp-1-era
-date: 2026-01-09
-domain: health
-secondary_domains: []
-format: article
-status: processed
-processed_by: vida
-processed_date: 2026-04-29
-priority: medium
-tags: [WeightWatchers, GLP-1, atoms-to-bits, belief-4, behavioral-health, telehealth, clinical-strategy]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-Published January 9, 2026. WeightWatchers (WW International) post-bankruptcy analysis:
-
-**Bankruptcy and restructuring:**
-- Filed Chapter 11 bankruptcy May 7, 2025 — to eliminate $1.15 billion in debt
-- New common equity (WW) listed July 2025, trading in $20 range
-- Full pivot to "clinical space"
-
-**Dual subscription model post-bankruptcy:**
-- "Lifestyle" segment: traditional behavioral coaching + app
-- "Clinical" segment (WW Clinic): telehealth, board-certified clinicians, GLP-1 prescribing (Wegovy, Zepbound) — the primary growth engine
-- WW Clinic was built on 2023 acquisition of Sequence ($106M)
-
-**Technology innovations announced:**
-- **AI Body Scanner (late 2025):** Smartphone-based body composition tracking (muscle mass vs. fat, not just weight)
-- **Weight Health Score:** Proprietary metric aggregating "data from wearable devices" to replace BMI for metabolic health
-- **Med+ Platform:** Dashboard for prescription management, side-effect tracking, clinician communication
-
-**What they are NOT doing:**
-- NO CGM (continuous glucose monitoring) integration announced
-- NO external biomarker testing (beyond their own AI Body Scanner)
-- NO partnership with Abbott FreeStyle Libre or similar physical data generation tools
-- Physical monitoring limited to existing consumer wearable device data aggregation
-
-**CEO strategy statement:**
-- New CEO Tara Comonte: "The Gold Standard of Weight Health" positioning
-- Focus on "biology and behavior" intersection
-- Avoiding "diet" vernacular entirely
-- Emphasizing "muscle preservation economy" — protein brand partnerships, muscle-mass tracking
-
-**Comparison to Session 30 taxonomy:**
-- Tier 3 (Clinical quality, minimal physical integration): WW Clinic is prescribing + behavioral, without physical data generation moat
-- Omada (Tier 4): CGM + behavioral + prescribing → profitable IPO at $1B valuation
-- WeightWatchers: prescribing + behavioral WITHOUT physical monitoring → bankruptcy → "rebirth" still without physical monitoring
-
-## Agent Notes
-
-**Why this matters:** Key generativity test for Belief 4 (atoms-to-bits is healthcare's defensible layer). Session 30 found a natural experiment: WW went bankrupt (behavioral only) while Omada IPO'd profitably (CGM + behavioral). The question now is: does WW's post-bankruptcy strategy REPLICATE the winning Omada model (adding physical monitoring), or does WW maintain behavioral+prescribing positioning?
-
-**What surprised me:** They are explicitly NOT adding CGMs. After the bankruptcy attribution (behavioral-only model failed), the obvious strategic response would be to add physical monitoring (CGM, biomarker testing) — the Noom December 2025 playbook. WW has the resources (debt eliminated, new investors) and the strategic urgency (need to differentiate). Yet the AI Body Scanner and "wearable data" integration is smartphone/consumer-grade, not clinical-grade physical monitoring.
-
-This is unexpected. Either: (A) WW leadership doesn't believe physical monitoring is the moat (testing Belief 4 from a different angle), or (B) they're building toward it but haven't announced it yet, or (C) they believe clinical depth/prescribing quality is sufficient moat (the Calibrate variant).
-
-**What I expected but didn't find:** CGM integration announcement, partnership with Abbott or Dexcom, or a biomarker testing integration like Noom's December 2025 at-home testing addition.
-
-**KB connections:**
-- Directly tests [[healthcares defensible layer is where atoms become bits because physical-to-digital conversion generates the data that powers AI care while building patient trust that software alone cannot create]]
-- References Omada vs. WW natural experiment from Session 30 archives
-- WW's bankruptcy was the "empirical falsification" of behavioral-only coaching (Session 30)
-
-**Extraction hints:**
-- NOT for immediate extraction — this is a WATCHING brief. WW rebirth without CGM is an ongoing test of Belief 4 generativity
-- MUSING NOTE: Flag for 2-3 session follow-up: "Has WW Clinic added physical monitoring?" If yes → Belief 4 is generative (others replicate). If no → either Belief 4 has a scope exception for clinical prescribing depth, or WW is going to fail again.
-- If WW Clinic shows clinical-grade adherence/outcomes WITHOUT physical monitoring → potential complication for Belief 4
-
-**Context:** January 2026 investor/analyst analysis. Most recent public strategic framing from WW post-bankruptcy. The company is in early days of rebirth — strategy will evolve.
-
-## Curator Notes
-
-PRIMARY CONNECTION: [[healthcares defensible layer is where atoms become bits because physical-to-digital conversion generates the data that powers AI care while building patient trust that software alone cannot create]]
-WHY ARCHIVED: Belief 4 generativity test. The natural experiment (WW vs. Omada) from Session 30 showed atoms-to-bits wins. Does WW follow the winning playbook? Currently: NO. This is a watching brief, not ready for extraction. Archive for follow-up in 2-3 sessions.
-EXTRACTION HINT: Hold for extraction until WW either adds physical monitoring or shows clinical outcomes data for the non-physical model. The current state is ambiguous.